PSTX News and Press, Poseida Therapeutics Inc. From 12/22/20

Gracell Biotechnologies has filed to raise $100 million in a U.S. IPO, although the final figure may vary. The firm is developing treatments for various cancers using a CAR-T approach. GRCL has produced very promising Phase 1 trial results for its lead candidate. For further...

Poseida Therapeutics Added to NASDAQ Biotechnology Index SAN DIEGO , Dec. 18, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and g...

Poseida Therapeutics Appoints Luke Corning to Board of Directors SAN DIEGO , Dec. 17, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create ce...

The following slide deck was published by Poseida Therapeutics, Inc. in conjunction with this event. For further details see: Poseida Therapeutics (PSTX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow

Poseida Therapeutics Provides Update on Phase 1 Trial of P-BCMA-101 at the 2020 American Society of Hematology Annual Meeting SAN DIEGO , Dec. 5, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage biopharmaceutical company utilizing proprieta...

Poseida Therapeutics (PSTX): Q3 GAAP EPS of -$0.63 misses by $0.08.Cash, cash equivalents and marketable securities of $341.5M.Press Release For further details see: Poseida Therapeutics EPS misses by $0.08

Poseida Therapeutics Reports Operational Update and Financial Results for Third Quarter 2020 PR Newswire SAN DIEGO, Nov. 12, 2020 SAN DIEGO , Nov. 12, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company u...

Poseida Therapeutics (PSTX) jumps 15% premarket on the heels of its announcement that the FDA has removed clinical holds on Phase 1 trial of P-PSMA-101 in metastatic castration-resistant prostate cancer; the company plans to resume the trial immediately.Last month, the tri...

Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer PR Newswire SAN DIEGO, Nov. 2, 2020 SAN DIEGO , Nov. 2, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmace...

Poseida Therapeutics ([[PSTX]] -0.1%) and TScan Therapeutics have entered into a research collaboration and license agreement to explore development of TCR-T cell therapies for the treatment of COVID-19.Poseida's allogeneic T cell platform will be used in combination with TScan's immunodomina...